MedTrace Logo

Effect of Lamotrigine on Cognition in NF1

NCT02256124 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2020-04-14

No results posted yet for this study

Summary

The purpose of this study is to determine whether lamotrigine can improve cognitive and neurophysiological deficits in adolescents with Neurofibromatosis type 1.

Conditions

  • Neurofibromatosis Type 1

Interventions

DRUG

Lamotrigine

DRUG

Placebo

Sponsors & Collaborators

  • Universitaire Ziekenhuizen KU Leuven

    collaborator OTHER

  • ZonMw: The Netherlands Organisation for Health Research and Development

    collaborator OTHER

  • Hospital Sant Joan de Deu

    collaborator OTHER

  • Erasmus Medical Center

    lead OTHER

Principal Investigators

  • Ype Elgersma, PhD · Erasmus Medical Center

  • Henriette A Moll, MD, PhD · Erasmus Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-10-31
Primary Completion
2020-04-30
Completion
2020-04-30

Countries

  • Belgium
  • Netherlands
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02256124 on ClinicalTrials.gov